Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma.
Erazo T, Evans CM, Zakheim D, Chu KL, Refermat AY, Asgari Z, Yang X, Da Silva Ferreira M, Mehta S, Russo MV, Knezevic A, Zhang XP, Chen Z, Fennell M, Garippa R, Seshan V, de Stanchina E, Barbash O, Batlevi CL, Leslie CS, Melnick AM, Younes A, Kharas MG. Erazo T, et al. Among authors: batlevi cl. Nat Commun. 2022 Sep 27;13(1):5676. doi: 10.1038/s41467-022-33137-8. Nat Commun. 2022. PMID: 36167829 Free PMC article.
Novel therapy for Hodgkin lymphoma.
Batlevi CL, Younes A. Batlevi CL, et al. Hematology Am Soc Hematol Educ Program. 2013;2013:394-9. doi: 10.1182/asheducation-2013.1.394. Hematology Am Soc Hematol Educ Program. 2013. PMID: 24319210 Review.
Novel immunotherapies in lymphoid malignancies.
Batlevi CL, Matsuki E, Brentjens RJ, Younes A. Batlevi CL, et al. Nat Rev Clin Oncol. 2016 Jan;13(1):25-40. doi: 10.1038/nrclinonc.2015.187. Epub 2015 Nov 3. Nat Rev Clin Oncol. 2016. PMID: 26525683 Free PMC article. Review.
Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.
Intlekofer AM, Joffe E, Batlevi CL, Hilden P, He J, Seshan VE, Zelenetz AD, Palomba ML, Moskowitz CH, Portlock C, Straus DJ, Noy A, Horwitz SM, Gerecitano JF, Moskowitz A, Hamlin P, Matasar MJ, Kumar A, van den Brink MR, Knapp KM, Pichardo JD, Nahas MK, Trabucco SE, Mughal T, Copeland AR, Papaemmanuil E, Moarii M, Levine RL, Dogan A, Miller VA, Younes A. Intlekofer AM, et al. Among authors: batlevi cl. Blood Cancer J. 2018 Jun 12;8(6):60. doi: 10.1038/s41408-018-0089-0. Blood Cancer J. 2018. PMID: 29895903 Free PMC article.
Surrogate end points in lymphoma.
Batlevi CL, Younes A. Batlevi CL, et al. Ann Oncol. 2018 Aug 1;29(8):1622-1623. doi: 10.1093/annonc/mdy219. Ann Oncol. 2018. PMID: 29905757 Free article. No abstract available.
Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma.
Umakanthan JM, Iqbal J, Batlevi CL, Bouska A, Smith LM, Shostrom V, Nutsch H, William BM, Gregory Bociek R, Lunning M, Bierman P, Younes A, Armitage JO, Vose JM. Umakanthan JM, et al. Among authors: batlevi cl. Br J Haematol. 2019 Mar;184(5):744-752. doi: 10.1111/bjh.15702. Epub 2018 Dec 5. Br J Haematol. 2019. PMID: 30520026 Free PMC article. Clinical Trial.
49 results